RADICAVA ORS Drug Patent Profile

« Back to Dashboard

When do Radicava Ors patents expire, and what generic alternatives are available?

Radicava Ors is a drug marketed by Shionogi and is included in one NDA. There are twelve patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in RADICAVA ORS is edaravone. Four suppliers are listed for this compound. Additional details are available on the edaravone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Radicava Ors

A generic version of RADICAVA ORS was approved as edaravone by GLAND on May 6^th, 2024.

Summary for RADICAVA ORS

US Patents:	12
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RADICAVA ORS

Paragraph IV (Patent) Challenges for RADICAVA ORS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RADICAVA ORS	Oral Suspension	edaravone	105 mg/5 mL	215446	1	2023-04-20

US Patents and Regulatory Information for RADICAVA ORS

RADICAVA ORS is protected by twelve US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes
Shionogi	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes			Y
Shionogi	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes

International Patents for RADICAVA ORS

When does loss-of-exclusivity occur for RADICAVA ORS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

China

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Mexico

Philippines

Poland

Portugal

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RADICAVA ORS around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	116967
Australia	2019369843
Australia	2025205635

Last updated: April 25, 2026

RADICAVA ORS: Investment Scenario and Fundamentals Analysis

What is RADICAVA ORS and how is it positioned commercially?

RADICAVA ORS is the oral formulation of edaravone, an ALS therapy. The branded product line includes RADICAVA (edaravone) intravenous and RADICAVA ORS (edaravone oral suspension), with the ORS product intended to shift administration away from IV infusion toward oral dosing.

From an investment perspective, the fundamentals hinge on three variables: (1) ALS treated population size and persistence, (2) dosing discipline and tolerability translating into adherence for oral therapy, and (3) pricing and payer coverage dynamics relative to competing standards and alternative edaravone access channels (including generic pathways after exclusivity).

---

What dosing, regimen, and clinical label define the addressable use?

FDA-approved indication (US):

• Amyotrophic Lateral Sclerosis (ALS)

Core clinical model:

• Edaravone is a disease-modifying option used in ALS with the product historically linked to specific trial inclusion criteria (which tends to translate into payer targeting and prescriber selection).

Dose form (oral suspension):

• RADICAVA ORS delivers edaravone as an oral suspension (exact mL-per-dose and dosing calendar are label-critical for pharmacy economics, but the investment thesis is primarily driven by whether the ORS regimen increases adherence versus IV schedules).

Investment implication:

• The market is not only “ALS patients,” but ALS patients who meet clinical selection patterns and persist long enough to generate repeat prescription volume.

---

How do payer dynamics and formulary access typically shape RADICAVA ORS revenue?

For specialty ALS drugs, revenue concentration often depends on:

• Formulary placement (preferred vs non-preferred)
• Prior authorization (PA) requirements anchored to activity measures and line-of-therapy rules
• Step edits (IV-to-oral switch criteria, where applicable)
• Manufacturing and distribution reliability, which can move payer behavior quickly when supply disruptions occur

Investment implication:

• ORS adoption depends on whether payers treat oral as “equivalent” to IV for coverage while still using the same evidence thresholds.

---

What does the competitive landscape look like for an edaravone oral franchise?

RADICAVA ORS competes within ALS on three axes:

1. Same-mechanism continuity: patients already on edaravone IV may transition to ORS if coverage supports it.
2. Other ALS disease-modifying agents: different mechanisms and evidence frameworks affect prescriber selection.
3. Access and administration burden: ORS can be advantaged if real-world patients cannot sustain IV schedules.

Investment implication:

• If ORS captures switch volume from IV without erosion from alternative mechanisms, it supports both unit growth and stickiness.

---

What is the demand profile and where is growth most likely to come from?

Demand in ALS specialty pharma follows four levers:

• Prevalence and diagnosis rate (population growth)
• Treatment penetration (share of diagnosed eligible patients receiving edaravone)
• Persistence (treatment duration and refill cadence)
• Switching behavior (IV to ORS or from oral initiation)

Investment implication:

• The growth case for RADICAVA ORS is typically strongest when oral dosing reduces logistical barriers and improves adherence, but it is constrained when eligibility filters or payer controls keep penetration flat.

---

What are the patent and exclusivity fundamentals that matter for investment timing?

Investment timing is driven by:

• Composition of matter (MoC) coverage on edaravone
• Formulation-specific and manufacturing/process claims for oral suspension
• Regulatory exclusivity, including:
  • Orphan Drug designation/exclusivity where applicable
  • New clinical or dosage form exclusivity if supported by FDA review history

Practical read-through for RADICAVA ORS:

• If MoC exclusivity on edaravone already anchors the overall molecule, RADICAVA ORS value depends on whether the oral suspension has additional enforceable barriers (formulation or process).

---

What is the revenue model and unit economics logic for an ALS oral suspension?

The unit economics of specialty oral drugs differ from IV primarily through:

• Site-of-care cost avoidance (patients do not require infusion center appointments)
• Simplified administration (home dosing)
• Different channel mix (specialty pharmacy vs infusion supply chain)

Investment implication:

• Even if the drug price is similar on a per-day basis, the cost-to-serve often improves for payers and patients, which can raise persistence and reduce churn.

---

What risks can compress value in RADICAVA ORS?

Key downside drivers in specialty ALS:

• Eligibility tightening: if payers narrow PA criteria for oral versus IV
• Utilization substitution: prescribers shift to alternative ALS therapies
• Switch friction: if clinicians resist switching stable patients from IV to ORS
• Adherence breakdown: oral regimens can face missed doses in the real world
• Pricing pressure: negotiation intensity with large payers grows with competitive entrants

Investment implication:

• The downside case is usually not demand collapse but lower than expected adherence and payer coverage breadth, which directly reduces refill density.

---

What is the upside case for RADICAVA ORS?

The bull case generally rests on:

• Increased ORS share through IV-to-oral switching
• Higher persistence due to reduced administration friction
• Broader payer adoption when evidence and utilization patterns support oral equivalence

Investment implication:

• Upside comes from conversion of logistical burden into treated-days.

---

How should investors diligence RADICAVA ORS fundamentals in practice?

An investment-grade checklist for ORS-specific diligence should include:

• Formulary footprint: preferred status and PBM coverage trend
• PA criteria: whether oral has the same clinical gate as IV
• Switch rate: percentage of IV patients moving to ORS over time
• Persistence and refill cadence: 3- and 6-month adherence markers for oral therapy
• Channel profitability: specialty pharmacy margins and distribution costs
• Manufacturing reliability: backorder frequency and lead times
• Competitive displacement metrics: share loss in patient cohorts starting new ALS therapy

Investment implication:

• For RADICAVA ORS, the differentiator is adoption and persistence, not new mechanism claims.

---

Key Takeaways

• RADICAVA ORS is the oral edaravone franchise within ALS, competing on access, adherence, and payer coverage rather than only on clinical mechanism.
• The investment case turns on IV-to-oral switching, real-world persistence, and formulary/PA breadth.
• The risk profile is dominated by payer restrictions, utilization substitution to other ALS standards, and oral adherence discipline.
• Patent and exclusivity timing for an oral suspension depends on whether the product has defensible formulation/process claims beyond edaravone MoC.

---

FAQs

1) What is RADICAVA ORS?

RADICAVA ORS is oral edaravone in an ALS therapy category.

2) Why does the oral formulation matter to investors?

It can reduce administration friction versus IV, which can improve adherence and persistence and expand payer acceptance.

3) What are the main commercial drivers for RADICAVA ORS?

Formulary coverage, prior authorization criteria, switch rate from IV, and oral persistence.

4) What are the main risks?

Payer tightening, competitive substitution within ALS, switching resistance, and adherence shortfalls.

5) What diligence items most predict performance?

Look for coverage depth, PA stringency changes, refill cadence for oral therapy, and IV-to-ORS conversion.

---

References

[1] FDA. “RADICAVA ORS (edaravone) oral suspension” prescribing information and labeling. U.S. Food and Drug Administration. (Accessed via FDA Drugs@FDA label documents).